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We report on a sibling pair with the EPG5 c.1007A > G mutation who developed a
severe form of Vici syndrome and died in infancy. The c.1007A > G (p.Gln336Arg)
mutation, affecting the penultimate nucleotide and the splicing of exon 2 is the most
common mutation of EPG5 and is typically associated with a less devastating prog-
nosis: cardiomyopathy and cataract are less frequent consequences and the median
survival time is 78 months compared to an overall median survival of 42 months. The
less severe course related to c.1007A > G was formerly explained by the preserved
canonical splicing in 25% of the transcripts. In contrast, we found the messenger RNA
encoded by the c.1007A > G allele to be absent, explaining the severe course of the
disease. This family provides another example of phenotypic variability related to a
differential splicing.
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1 INTRODUCTION
Carlo Dionisi-Vici described two brothers with agenesis of
the corpus callosum, combined immunodeficiency, bilateral
cataract, and hypopigmentation in 1988 (Dionisi-Vici et al.,
1988). In addition to these phenotypic features, cardiomyopa-
thy, developmental delay, microcephaly, and failure to thrive
were described as typical consequences (Byrne et al., 2016c;
Chiyonobu et al., 2002; del Campo et al., 1999). Since the first
description, more than 40 families have been published with
Vici syndrome (VICIS), who were compatible with an auto-
somal recessive transmission and have extended the variable
clinical spectrum with myopathy, epilepsy, elevated amino-
transferases, thymus aplasia, thrombocytopenic purpura,
sensorineural hearing loss, and renal tubular acidosis (Aggar-
wal, Tandon, Bhowmik, & Dalal, 2018; Al-Owain et al.,
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2010; Alzahrani, Alghamdi, & Waggass, 2018; Balasubrama-
niam et al., 2018; Byrne et al., 2016c; Chiyonobu et al., 2002;
Cullup et al., 2013; del Campo et al., 1999; Demiral, Sen,
Esener, Ceylaner, & Tekedereli, 2018; El-Kersh, Jungbluth,
Gringras, & Senthilvel, 2015; Hedberg-Oldfors, Darin, &
Oldfors, 2017; Hori et al., 2017; Huenerberg et al., 2016;
Maillard et al., 2017; McClelland et al., 2010; Miyata et al.,
2007; Ozkale, Erol, Gümüs, Ozkale, & Alehan, 2012; Rogers,
Aufmuth, & Monesson, 2011; Said, Soler, & Sewry, 2012;
Shimada et al., 2018; Waldrop et al., 2018). The prognosis
was found to be poor with a median survival of 42 months
(Byrne, Dionisi-Vici, Smith, Gautel, & Jungbluth, 2016b).
There is, however, a significant difference in the severity and
the overall survival (Byrne et al., 2016c; Hori et al., 2017).
Mutations of EPG5 (18q12.3) were identified in 2013 by
whole exome sequencing (Cullup et al., 2013). The encoded
protein, ectopic P-granules autophagy protein 5 is a Rab7
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effector mediating the fusion specificity between autophago-
somes and lysosomes (Cullup et al., 2013; Hori et al., 2017;
Wang et al., 2016). Loss of EPG5 results in the accumulation
of autophagic cargo in autophagosomes (Byrne et al., 2016c;
Ehmke et al., 2014).
Most of the EPG5 mutations are null (Byrne et al., 2016c).
Patients with biallelic loss-of-function mutations typically
develop severe cardiomyopathy and immunodeficiency, lead-
ing to a markedly reduced life expectancy (Supplemental
Table 1; Byrne et al., 2016b).
The most common EPG5 mutation, reported in four unre-
lated families with Caucasian or Ashkenazi origin, is the
c.1007A > G mutation (rs201757275) with an allele fre-
quency of 2.85 × 10−5 in Europe (http://gnomad.broad
institute.org) (Byrne et al., 2016c). It causes an amino acid
substitution (p.Gln336Arg) and, affecting the penultimate
nucleotide of the second exon, leads to aberrant splicing and
messenger RNA (mRNA) decay in 75% and 50% of the tran-
scripts (Byrne, Cullup, Fanto, Gautel, & Jungbluth, 2016a;
Kane et al., 2016). The preserved canonical splicing in 25%
of the transcripts allows the phenotype to be generally milder
with a median survival time of 78 months. Accordingly, none
of the four previously reported children with c.1007A > G
developed severe cardiomyopathy and only two of them
developed cataract (Supplemental Table 1; Byrne et al.,
2016c).
Here we present two siblings with the c.1007A > G muta-
tion who presented with an unexpectedly severe phenotype
and died in infancy. We found all mRNA expressed from the
c.1007A > G allele to be decayed, emphasizing the interfa-
miliar variability of splicing and the potential severity of the
c.1007A > G mutation.
The index case was the third child of a nonconsanguineous
Hungarian couple (Figure 1). The first child was born pre-
maturely at the 31st gestational week with a normal length,
weight, and head circumference. On examination, she had
pale skin throughout her body and fair, sparse hair. Fun-
doscopy described stage I retinopathy of prematurity. Cra-
nial ultrasound scan showed agenesis of the corpus callo-
sum and cavum septum pellucidi. She presented with multiple
episodes of aspirations, pneumonias, and a rotavirus gastroen-
teritis, and was diagnosed with generalized hypotonia, gas-
troesophageal reflux disease, and bilateral cataract by the age
of 2 months. She did not acquire social smile throughout her
life, failed to fix and follow at 3 months of age, and brain-
stem auditory-evoked responses supported the diagnosis of
sensorineural hearing loss. At 5 months of age, she developed
cardiomegaly with a cardiothoracic ratio of 0.75. Echocardio-
graphy showed bicuspid aortic valve and dilated cardiomy-
opathy with a progressive left ventricular dilatation (left ven-
tricular end diastolic and end systolic diameter z-scores of
3.1 were 5.8, respectively), interventricular septal hypoki-
nesis, and depressed ventricular function with a fractional
shortening of 17%. She deteriorated quickly despite the com-
bined therapy of digoxin, dopamine, dobutamine, furosemide,
and captopril. Progressive failure to thrive resulted in severe
F I G U R E 1 Pedigree (a) and phenotype (b) of the index patient. Note the oculocutan hypopigmentation, low set ears, and syndactyly of the
second and third toes (b). Feeding difficulties necessitated nasogastric tube feeding [Colour figure can be viewed at wileyonlinelibrary.com]
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hypotrophy, her weight dropped below the 0.4th centile at
6 months of age, when she died as a result of cardiac failure.
The second child is a healthy male adolescent.
The third child was a male, born 15 years after the first
child from an uneventful pregnancy at term, with a normal
weight, length, and head circumference (50th, 75th and 50th
centiles, respectively). Physical examination revealed marked
generalized oculocutan hypopigmentation, syndactyly of
the 2nd and 3rd toes, low set ears, and severe hypotonia
(Figure 1). Fundus examination revealed hypopigmentation.
He developed apneas as a result of paroxysmal seizure
activity as shown by an electroencephalogram. His seizures
were resistant to a combined antiepileptic therapy of pheno-
barbital and phenytoin. Brain magnetic resonance imaging
was consistent with VICIS showing cerebellar and brainstem
hypoplasia, agenesis of the corpus callosum, dilated lateral
ventricles, and small hippocampi. Routine laboratory inves-
tigations showed increased serum aspartate aminotransferase
(111 U/L), alanine aminotransferase (124 U/L), lactate dehy-
drogenase (870 U/L), and creatine kinase and (841 U/L). He
was treated for multiple septic episodes secondary to Candida
albicans, Pseudomonas aeruginosa, and Stenotrophomonas
maltophilia infections after the age of 2 weeks. The infec-
tions necessitated combined antibiotic treatment (including
fluconazole for C. albicans, piperacillin/tazobactam for P.
aeruginosa, and trimethoprim/sulfamethoxazole for S. mal-
tophilia) and intravenous immunoglobulin supplementation.
Recurrent unexplained fevers were common. Immunological
workup showed normal T-cell subtype count, slightly ele-
vated IgA (0.2 g/L), IgM (0.5 g/L), and low IgG (4.3 g/L)
at 6 weeks of age. He was also diagnosed with a moderate
dilated cardiomyopathy at 1 month of age with an ejection
fraction of 37%, a grade II mitral and a grade I tricuspid
regurgitation, and a left ventricular overload. He was started
on furosemide and was followed up by a pediatric cardiologist
in every second week. Severe gastroesophageal reflux disease
necessitated an elective Nissen fundoplication and gastrotube
insertion. Muscle biopsy confirmed marked variability in
fiber size, centralized nuclei, and numerous large vacuoles
on light microscopy.
At 6 weeks of age, he was diagnosed with cataract
and secondary microcephaly (<9th centile), generalized
muscle hypotonia, severe hypotrophy, and thoracolumbar
kyphoscoliosis. Neurodevelopmental examination suggested
sensorineural hearing loss. After establishing the diagno-
sis of Vici syndrome, the unfavorable prognosis was dis-
cussed with the family. The parents participated in a basic
life support course and decided to take their child home when
he was stable and well. Sorrowfully, 3 days later, he was
readmitted for a new-onset sepsis. Repeated blood, urine,
and cerebrospinal fluid cultures were negative. Despite the
treatment with multiple combinations of broad-spectrum
antibiotics (including piperacillin/tazobactam, meropenem,
vancomycin, trimethoprim/sulfamethoxazole, fluconazole,
and ceftriaxone) and intravenous immunoglobulins, he died 2
weeks later at the age of 3 months because of an overwhelm-
ing sepsis. Genetic counseling was provided to the parents.
2 MATERIALS AND METHODS
Genomic DNA was extracted based on proteinase K digestion
followed by high-sodium chloride treatment to precipitate
proteins. The coding exons and the splicing junctions
of EPG5 (NM_020964) were Sanger sequenced in the
Genetics Department of Guy’s and St Thomas’ Hospital,
London, using primers as described previously (Cullup et al.,
2013). Parental samples were Sanger sequenced to confirm
transheterozygosity.
Total RNA was extracted from parental leukocytes with
Macherey–Nagel NucleoSpin RNA Blood kit. No RNA was
available from the affected child. The RNA samples were
reverse-transcribed using the Thermo Fisher Maxima First
Strand reverse transcription kit.
Parental complementary DNAs (cDNAs) were Sanger
sequenced using MyTaq HS Mix (Bioline, London, UK).
The primers TTCATGGCTGGAAAATGTTG (forward),
GCACGGATACCAATTTCTGC (reverse), and ACCG-
GAGTCTGCTCTCATCT (forward), GGGGGTGATCA-
GAAGGTGTG (reverse) were used to amplify the regions
encompassing the c.1007A > G maternal and the c.3768delA
paternal mutations, respectively.
The amount of the c.1007A>G maternal mRNA
was studied by quantitative polymerase chain reaction
(qPCR) of cDNA with allele-specific primers: GAG-
GAACAAATGTCTGTACA (wild-type forward), GAG-
GAACAAATGTCTGTACG (c.1007A>G forward), and
AAGAATGAAGGGCCAGGGTC (reverse). The initial
denaturation (95◦C for 5 min) was followed by 40 cycles
of amplification (95◦C for 5 s, 60◦C for 5 s, 72◦C for 7 s).
The specificity of the c.1007A>G forward primer was vali-
dated with maternal genomic DNA (Supplemental Figure 1).
Dilution series of a control cDNA was used to calculate
the efficiency of the qPCR (Supplemental Figure 2). The
qPCR was carried out on a LightCycler 480 system (Roche
Diagnostics, Mannheim, Germany) with LightCycler 480
SYBR Green I Master enzyme mix (Roche Diagnostics).
To detect the splice isoforms encoded by the c.1007A > G
allele, reverse transcription quantitative multiplex PCR of
short fluorescent fragments (RT-QMPSF) was developed
using the primers 2F_QMPSF: AGCATGGCTCATCAA-
GACAG and 3R_QMPSF: AGCTCCACCAGTGCATTTTC
with universal tags (Carrington, Varshney, Burgess, &
Sood, 2015). Briefly, a short cDNA sequence (275 bp)
encompassing exons 2 and 3 was amplified with MyTaq
HS Mix (Bioline) with the following conditions: the initial
denaturation (95◦C for 2 min) was followed by 30 cycles
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F I G U R E 2 Absence of maternal c.1007A > G
mRNA and splice isoforms. While a low amount of the
paternal c.3768delA messenger RNA (mRNA) is
detectable on sequence chromatogram (a), the maternal
c.1007A > G mRNA is not (b). (c) Quantitative real-time
polymerase chain reaction (PCR) of the mutant and the
wild-type (wt) alleles reveal no mutant complementary
DNA (cDNA) in the maternal sample. Agarose gel
electrophoresis indicate the specific wt bands and
confirm the lack of amplification of the mutant cDNA
from the maternal sample (C: control cDNA, M:
maternal cDNA, mut: mutant allele-specific PCR,
MWM: molecular weight marker, wt: wt allele-specific
PCR, “-”: no template control). (d) Reverse transcription
quantitative multiplex PCR of short fluorescent fragment
(RT-QMPSF) shows no difference between the control
and the maternal samples, indicating the lack of splice
isoforms of the c.1007A > G allele [Colour figure can be
viewed at wileyonlinelibrary.com]
of amplification (95◦C for 15 s, 60◦C for 20 s, 72◦C for
15 s) and a final extension (72◦C for 5 min). Fluorescent
amplicons were separated on an ABI prism 3100 genetic
analyzer (Thermo Fisher Scientific, Waltham, MA), and the
resulting fluorograms were analyzed using the Peak Scanner
Software 2.0 (Thermo Fisher Scientific).
3 RESULTS AND DISCUSSION
The presence of the eight principal features of Vici syn-
drome (agenesis of the corpus callosum, recurrent infec-
tions, cataract, oculocutaneous hypopigmentation, cardiomy-
opathy, failure to thrive, progressive microcephaly, and
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profound developmental delay) was found to have a specificity
of 97%, and a sensitivity of 89% for a positive EPG5 genetic
test (Byrne et al., 2016c). In the presented family, the male
patient displayed all eight key symptoms in the first 3 months
of his life, emphasizing the severe course of the disease.
He also developed myopathy, elevated liver enzymes, and
intractable seizures, which were previously proposed to be
typical features in Vici syndrome. Moreover, he suffered from
severe gastroesophageal reflux disease similarly to four pre-
viously reported patients for whom Nissen fundoplication or
gastrostomy was necessitated (Balasubramaniam et al., 2018;
Huenerberg et al., 2016; Shimada et al., 2018; Tasdemir et al.,
2016). Gastroesophageal reflux disease may be therefore con-
sidered as part of the associated clinical spectrum. Intractable
diarrhea developed in the female patient and was suggested to
be secondary to malabsorption. This consequence is supposed
to be linked to EPG5-related autophagy depletion (Alzahrani
et al., 2018; Hedberg-Oldfors et al., 2017; Huenerberg et al.,
2016; Shimada et al., 2018).
In accordance with the clinical diagnosis, the index patient
was found to be compound heterozygous for the maternal
c.1007A>G and the paternal c.3768delA EPG5 mutations
(Figure 2a,b). Corresponding to the close localization of
the premature stop codon to an exon–intron boundary
(38 bp upstream) (Maquat, 2004), we found the paternal
mutant mRNA to be only partially decayed (Figure 2).
However, the c.3768delA leads to premature truncation,
producing a half-length, presumably dysfunctional protein
(p.Glu1258Asnfs*3).
The maternal c.1007A>G was not detectable on the
sequence chromatogram of the cDNA (Figure 2). Accord-
ingly, we detected no c.1007A>G mRNA by allele-specific
qPCR in the maternal sample (Figure 2). Several splice iso-
forms have been described in a patient with homozygous
c.1007A>G, three major ones being present in 72% of the
transcripts (Kane et al., 2016). However, we found no alter-
native splice isoforms by RT-QMPSF in the maternal sam-
ple, further supporting the different effect of the c.1007A > G
mutation in the presented family (Figure 2).
Based on these findings, the two affected siblings had
no functional EPG5 protein. This contrasts previous find-
ings in the patient with the c.1007A>G mutation in whom
25% of the transcripts are spliced normally, and encode only
the p.Gln336Arg substitution (Kane et al., 2016). The two
siblings herein presented with early-onset cardiomyopathy,
cataract, and severe immunodeficiency: a severe phenotype
typical for patients with biallelic loss-of-function EPG5 muta-
tions, but uncommon in patients with c.1007A > G (Sup-
plemental Table 1). We thus hypothesize that the severe
clinical course is explained by the lack of the canonical
splicing and a complete mRNA decay. Similarly, a signif-
icant interfamilial phenotype variability related to noncon-
sensus splicing mutations was observed in cystic fibrosis,
highlighting that splicing factors can modulate the effect of
the mutations on the splicing pattern of CFTR alleles (Chiba-
Falek et al., 1998; Nissim-Rafinia, Chiba-Falek, Sharon,
Boss, & Kerem, 2000). These support that the effect of the
nonconsensus splice site mutations may be variable among
families.
In conclusion, we infer that there is interfamilial variability
in the splicing of the EPG5 c.1007A>G allele, and the related
phenotype can be severe.
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